Physician profile
Daljit Sawhney
NPI 1568487742
$1,844.04
in general payments reported to CMS, 2019-2025
17 companies · $224 in 2025
The $224 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $18.96 · 2021: $170 · 2022: $248 · 2023: $432 · 2024: $416 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $978 · Education: $92.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.49 |
| Education | $92.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.39 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $273.83 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.50 | 2019-2023 | Synjardy, Jardiance |
| Lilly USA, LLC | $170.94 | 2019-2025 | Jardiance, Emgality, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $128.89 | 2021-2024 | |
| Novo Nordisk INC | $107.40 | 2022-2023 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $94.62 | 2019-2022 | |
| Glaxosmithkline, LLC. | $90.84 | 2019-2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $73.11 | 2019-2023 | |
| Abbvie INC. | $56.31 | 2021-2024 | |
| Ascensia Diabetes Care US INC. | $41.70 | 2019 | |
| Astellas Pharma US INC | $39.46 | 2023 | Veozah |
| Exact Sciences Corporation | $21.53 | 2025 | The Cologuard Plus Collection Kit |
| Seqirus USA INC | $20.67 | 2024 | Flucelvax, Fluad |
| Janssen Pharmaceuticals, INC | $17.49 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.66 | 2019 | |
| Merck Sharp & Dohme LLC | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daljit Sawhney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.